Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis

Amsterdam, NH Doing business as Stichting Nki-Avl

UEI
JSPLXWM8LFQ9
CAGE
H1E26
Primary NAICS
541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • Non-Profit Organization
  • Foundation
Entity structure
Other
SAM.gov registration date
Physical address
Plesmanlaan 121, 1066 CX Amsterdam, Netherlands
Website
nki.nl
Founded
1913
Employees
1K-5K
Estimated annual revenue
$250M-$500M
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Biotechnology
SIC code
87 Engineering & Management Services

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Contract obligations by fiscal year

Fiscal year Obligated
FY2027 To date $0
FY2026 $0
FY2025 $0
FY2024 $0
FY2023 $68,640

Contract awards

Award Agency Obligated Awarded
This purchase order includes services to collect, harmonize and manage clinical trial data being contributed to the… 75N91023P00738 National Cancer Institute (NIH) $68,640
To collect, harmonize and manage pathology treatment and survival data that is being contributed to the confluence… 75N91020P00600 National Cancer Institute (NIH) $315,770
Provide statistical analysis support for formaldehyde study per statement of work. HHSN261200800497P National Cancer Institute (NIH) $10,000
Statistical analysis and conference attendance. HHSN261200700200P National Cancer Institute (NIH) $0
O consultation on formaldeyde studies per statement of work. HHSN2612006MQ609484P National Cancer Institute (NIH) $12,710

Grant awards

Award Agency Obligated Awarded
Quantitative background parenchymal enhancement, measured on contrast-enhanced mammogram, as a novel marker of breast… R37CA284134 National Cancer Institute (NIH) $508,662
The role of the hippo pathway on mammalian organ size, progenitor cells and cance R01CA131426 National Institutes of Health $1,244,005
Risk and prognosis of uterine corpus cancer after tamoxifen treatment for breast R03CA130108 National Institutes of Health $54,734

Grant subawards

Prime recipient Prime award Amount Awarded
Emory University Defining clinically actionable subtypes of castration-resistant prostate cancer HT94252310048 $13,766
Sloan-Kettering Institute For Cancer Research Dr. van Leeuwen will serve as a close advisor to Drs. Henderson and Moskowitz on all aspects ofthe grant including the harmonization process, the data analysis,… R01CA268143 $32,856

Similar vendors

Vendor Location Primary NAICS
Aacr UEI K4LZTWHBSGN6 Philadelphia, PA 813920 Professional Organizations
Dkfz UEI HN6NKBK47VJ1 Heidelberg, BW 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
NRG Oncology Foundation Inc. UEI TUS8D6ZGL9R3 Philadelphia, PA —
Kraeftens Bekaempelse UEI YTLZDMD7Y7K3 København 813212 Voluntary Health Organizations
Pink Ribbon Classic UEI EHTKDK18LYH7 Atlanta, GA —

See more similar vendors on GovTribe

About the company

Written by GovTribe AI ·

Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis, doing business as Stichting Nki-Avl, is a non-profit organization and foundation registered in SAM.gov, specializing in cancer research and clinical data management. Located in Amsterdam, Netherlands, the organization provides specialized services to U.S. federal agencies, particularly the National Cancer Institute (NCI). As a research-focused institution, Stichting Nki-Avl contributes to international cancer research efforts through data collection, harmonization, and management of clinical trials and pathological information.

In terms of federal contract awards, Stichting Nki-Avl has been awarded two purchase orders from the National Cancer Institute, totaling $384,410. These contracts are focused on collecting, harmonizing, and managing clinical trial data for the Confluence Project, an international cancer research collaboration. The first contract, valued at $68,640, involves collecting European clinical trial data, while the second contract, valued at $315,770, focuses on collecting pathology treatment and survival data from the Breast Cancer Association Consortium. Both contracts are firm fixed-price purchase orders with no specific set-aside designations and are designed to support NCI's mission of facilitating cancer research data sharing.

For federal grant awards, Stichting Nki-Avl has been involved in significant research projects, including a recent National Cancer Institute grant (R37CA284134) focused on quantitative background parenchymal enhancement as a marker of breast cancer risk. The organization has also participated in sub-grant awards with prominent cancer research institutions like Sloan-Kettering Institute and Dana-Farber Cancer Institute. These sub-grant awards involve collaborative research efforts, including functional studies of metastasis-specific AR binding sites, CRISPR-Cas9 research on prostate cancer cell lines, and advisory roles in data analysis and manuscript preparation. The grants demonstrate Stichting Nki-Avl's expertise in advanced cancer research methodologies, including molecular biology, genetic engineering, and clinical data interpretation.

Quick answers

Is Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis registered in SAM.gov?

Yes. Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis's SAM.gov registration is active through September 20, 2027.

What is Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis's CAGE code?

Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis's CAGE code is H1E26, and its Unique Entity ID (UEI) is JSPLXWM8LFQ9.

How much has Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis received in federal contracts?

Federal contracts obligated $68,640 to Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis in fiscal years 2023 through 2027.

What is Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis's most recent federal award?

Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis's most recent federal grant award is Quantitative background parenchymal enhancement, measured on contrast-enhanced mammogram, as a novel marker of breast… (R37CA284134), from National Cancer Institute (NIH), on April 2, 2024.

On GovTribe

See Stichting Het Nederlands Kanker Instituut-Antoni Van Leeuwenhoek Ziekenhuis's full federal record

  • Federal contract awards
  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login

Find teaming partners on GovTribe